A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
Latest Information Update: 27 Aug 2023
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
- Indications Breast cancer; Malignant-mesothelioma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
- Focus Adverse reactions
- Acronyms MpeTK01
- Sponsors Advantagene; Candel Therapeutics
- 02 Dec 2020 Status changed from active, no longer recruiting to completed.
- 18 Oct 2017 Results assessing safety presented at the 18th World Conference on Lung Cancer.
- 07 Jun 2016 Results assessing safety of AdV-tk theray presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.